(Q35594000)

9 August 2017

1 reference

title

Aprepitant--a novel NK1-receptor antagonist (English)

1 reference

9 August 2017

Lisa Patel

1

1 reference

PubMed ID

14640927

9 August 2017

Celeste Lindley

series ordinal

2

1 reference

PubMed ID

14640927

9 August 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

Expert Opinion on Pharmacotherapy

9 August 2017

1 reference

9 August 2017

4

1 reference

9 August 2017

12

1 reference

9 August 2017

2279-2296

1 reference

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

9 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

The changeable nature of patients' fears regarding chemotherapy: implications for palliative care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Quality of life consequences of chemotherapy-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Prevention and treatment of postoperative nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Potential of substance P antagonists as antiemetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Substance P: a pioneer amongst neuropeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Substance P: a new era, a new role

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

The tachykinin NK1 receptor in the brain: pharmacology and putative functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2279

10.1517/14656566.4.12.2279

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14640927